Adenosine Cyclophosphate

In the clinical treatment of cardiovascular diseases and respiratory diseases, cell signaling pathway regulating drugs have always been an important direction for optimizing treatment regimens. As a nucleotide-type second messenger in cells, cyclic adenosine monophosphate (cAMP) activates protein kinase A to regulate intracellular glucose and lipid metabolism as well as gene expression, and meanwhile exerts pharmacological effects of relaxing smooth muscle, enhancing myocardial contractility and improving myocardial ischemia. It is mostly used clinically as adjuvant therapy for cardiovascular diseases such as myocarditis, myocardial infarction and cardiogenic shock, and can also be used in combination with other drugs to improve respiratory symptoms in patients with bronchitis and asthma. The applicable population covers adults and elderly patients with chronic diseases who need dose adjustment.

The global market size of cyclic adenosine monophosphate API has maintained a steady growth trend in recent years. In 2023, the market size was approximately USD 120 million, with a compound annual growth rate of around 6.8%. Driven by the rising prevalence of chronic diseases and the expansion of primary diagnosis and treatment demand in the domestic market, the consumption exceeded 180 tons in 2023. Local enterprises are the main suppliers, and the production capacity of leading manufacturers accounts for more than 65% of the total domestic production capacity. Driven by the centralized procurement policy, the cost of preparations continues to decline, which also drives the steady increase in demand for upstream APIs.

The original developer of cyclic adenosine monophosphate is Eisai Co., Ltd. of Japan, with the original brand name "Meixinli". The core compound patent of the product expired globally in 2010. At present, the main marketed dosage form of the original product is injection, with specifications including 20mg/vial and 40mg/vial, which has been included in the Chinese Catalog of Reference Listed Drugs for Chemical Products. According to the information on the domestic API registration platform, 12 enterprises have obtained A-status registration numbers for their cyclic adenosine monophosphate APIs. Corresponding preparation varieties such as cyclic adenosine monophosphate for injection and cyclic adenosine monophosphate glucose injection have all been approved for marketing in China. (Data as of October 2024, please refer to the official website of CDE for the latest information)

CATO provides a full set of impurity reference standards for this API, covering the full product spectrum including synthetic process impurities and degradation impurities, most of which are in stock. Orders placed before 16:00 can be shipped on the same day. All products meet the requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the needs of API manufacturers for quality research, release testing and declaration and registration.